DHR Stock Price Today (July 2026) — Danaher Corporation Analysis & Key Metrics 2026-07-17
Danaher Corporation (DHR) is trading at $203.83, down 0.58% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $242.35 (18.9% upside).
- Volatility remains elevated (21.56% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (3.70% YoY) alongside significant competitive pressures.
DHR Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Danaher Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $148.81B
P/E Ratio
Forward P/E: 21.06
Revenue Growth
Year over Year
Analyst Target
+18.9% upside potential
Key Investor Questions About DHR
What investors need to know before buying
Based on current market data, DHR presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 67.67)
- Fundamentals say: Caution warranted (high leverage concerns)
DHR's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for DHR investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $19.68B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, DHR stock traded between $160.93 and $242.80—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 21.56% annualized volatility and β=0.89, the stock exhibits moderate correlation to market moves—making DHR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Abbott Just Showed Its Growth Engine Has More Than One Cylinder
The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.
The Zacks Analyst Blog Highlights Interactive Brokers, Danaher, S&P Global and Optical Cable
Interactive Brokers leads Zacks' featured research, with reports also spotlighting Danaher, S&P Global and Optical Cable's growth drivers and risks.
Can Abbott Stock Deliver on Its Second-Half Growth Promise?
This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.
Danaher (DHR) Is Expanding Diagnostics With A StatLab Medical Products Deal
Leica Biosystems, part of Danaher, has entered a definitive agreement to acquire StatLab Medical Products. The deal expands Danaher's diagnostics and anatomical pathology offering and adds more consumables and instruments to its portfolio. This development is relevant for investors tracking NYSE:DHR, as it focuses attention on the diagnostics segment. Danaher, traded as NYSE:DHR, is leaning further into diagnostics through Leica Biosystems' planned acquisition of StatLab Medical Products...
Danaher (DHR) Stock May Trade At A Discount Despite Its 18% Five Year Decline
Danaher stock presents a clear valuation tension right now, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the earnings based multiples suggest the shares are already pricing in a premium. Over the past 5 years, Danaher shareholders have seen the stock decline about 18%, which frames the current valuation debate against a weaker long term return profile. Recent news around portfolio moves in diagnostics and pathology can support expectations...
Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)?
Danaher, which released its Q2 2026 results on 21 July, saw expectations firm up ahead of the report as analysts projected modest year-on-year growth in revenue and earnings, helped by solid bioprocessing demand, improved filtration activity, and contributions from the Masimo acquisition despite cost pressures and higher debt. Investors are focusing on how Masimo’s integration and continued strength in bioprocessing and diagnostics could offset weaker areas like Diagnostics and rising input,...
Top Research Reports for Interactive Brokers, Danaher & S&P Global
Interactive Brokers, Danaher and S&P Global lead today's featured research, highlighting key growth drivers, challenges and performance trends.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?
DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.
Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Frequently Asked Questions
Common investor questions about Danaher Corporation
Danaher Corporation (DHR) is currently trading at $203.83. The RSI (14-day) is at 67.7, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $242.35 implies 18.9% upside from current levels. Volatility is moderate at 21.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Danaher Corporation (DHR): The trailing P/E ratio is 39.50, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 21.06, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.22, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.72. Price-to-Sales is 5.82. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 23 analysts covering DHR, the consensus price target is $242.35. This represents a 18.9% upside from the current price of $203.83. The range spans from a low target of $200.00 to a high target of $310.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Danaher Corporation (DHR) pays a dividend with a current yield of approximately 78.00%. The annualized dividend rate is $1.36 per share. The payout ratio is 26.4%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-06-26T00:00:00.000Z.
Key risks for Danaher Corporation (DHR) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Danaher Corporation's (DHR) current debt and financial health profile: Total debt stands at $19.68B. The debt-to-equity ratio is 37.17, which is moderate and generally manageable for most companies. The current ratio is 1.87, indicating strong short-term liquidity. The quick ratio is 1.40. The company holds $5.70B in cash and equivalents. Free cash flow is positive at $4.57B, providing a cushion for debt servicing and shareholder returns.